Michel Chonchol
Concepts (708)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 87 | 2025 | 653 | 11.210 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 36 | 2026 | 235 | 9.860 |
Why?
| | Kidney Failure, Chronic | 57 | 2026 | 598 | 7.150 |
Why?
| | Glomerular Filtration Rate | 92 | 2026 | 760 | 6.100 |
Why?
| | Renal Dialysis | 35 | 2026 | 462 | 5.840 |
Why?
| | Kidney | 51 | 2026 | 1495 | 5.500 |
Why?
| | Kidney Diseases | 33 | 2025 | 427 | 4.830 |
Why?
| | Fibroblast Growth Factors | 25 | 2020 | 188 | 4.700 |
Why?
| | Cardiovascular Diseases | 57 | 2023 | 2168 | 4.060 |
Why?
| | Vitamin D | 31 | 2022 | 400 | 3.710 |
Why?
| | Hypertension | 37 | 2022 | 1263 | 2.700 |
Why?
| | Vitamin D Deficiency | 13 | 2024 | 186 | 2.550 |
Why?
| | Vascular Stiffness | 20 | 2025 | 486 | 2.380 |
Why?
| | Phosphates | 12 | 2024 | 180 | 2.270 |
Why?
| | Endothelium, Vascular | 18 | 2025 | 965 | 2.270 |
Why?
| | Disease Progression | 44 | 2026 | 2847 | 2.240 |
Why?
| | Kidney Calculi | 5 | 2024 | 45 | 2.140 |
Why?
| | Blood Pressure | 35 | 2023 | 1769 | 2.090 |
Why?
| | Nutrition Surveys | 15 | 2024 | 282 | 2.060 |
Why?
| | Phosphorus | 13 | 2017 | 99 | 1.940 |
Why?
| | Aged | 176 | 2026 | 25913 | 1.870 |
Why?
| | Middle Aged | 173 | 2026 | 35875 | 1.850 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2025 | 439 | 1.830 |
Why?
| | Blood Vessels | 4 | 2024 | 171 | 1.820 |
Why?
| | Oxidative Stress | 21 | 2026 | 1339 | 1.800 |
Why?
| | Male | 237 | 2026 | 72315 | 1.770 |
Why?
| | Uric Acid | 12 | 2021 | 166 | 1.760 |
Why?
| | Nephrology | 5 | 2022 | 60 | 1.750 |
Why?
| | Humans | 312 | 2026 | 144759 | 1.720 |
Why?
| | Female | 236 | 2026 | 78271 | 1.690 |
Why?
| | Cholecalciferol | 6 | 2024 | 60 | 1.660 |
Why?
| | Creatinine | 25 | 2021 | 506 | 1.630 |
Why?
| | Risk Factors | 91 | 2025 | 10779 | 1.580 |
Why?
| | Sodium, Dietary | 4 | 2024 | 37 | 1.560 |
Why?
| | Inflammation | 21 | 2025 | 2878 | 1.500 |
Why?
| | Potassium, Dietary | 3 | 2024 | 12 | 1.490 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 14 | 1.470 |
Why?
| | Double-Blind Method | 31 | 2025 | 2029 | 1.460 |
Why?
| | Parathyroid Hormone | 18 | 2020 | 112 | 1.440 |
Why?
| | Vascular Calcification | 8 | 2022 | 110 | 1.360 |
Why?
| | Dietary Supplements | 10 | 2021 | 576 | 1.310 |
Why?
| | Biomarkers | 45 | 2025 | 4271 | 1.270 |
Why?
| | Brachial Artery | 12 | 2025 | 206 | 1.260 |
Why?
| | Lanthanum | 4 | 2024 | 13 | 1.210 |
Why?
| | Pravastatin | 3 | 2025 | 43 | 1.160 |
Why?
| | Calcium | 13 | 2020 | 1183 | 1.150 |
Why?
| | Adult | 86 | 2026 | 40449 | 1.150 |
Why?
| | Antihypertensive Agents | 14 | 2021 | 510 | 1.090 |
Why?
| | Fatty Liver | 10 | 2013 | 251 | 1.080 |
Why?
| | Metabolic Syndrome | 7 | 2025 | 354 | 1.040 |
Why?
| | Coronary Disease | 7 | 2010 | 383 | 1.030 |
Why?
| | Naphthalenes | 4 | 2015 | 56 | 1.020 |
Why?
| | Pulse Wave Analysis | 12 | 2025 | 266 | 1.020 |
Why?
| | Bacterial Infections | 3 | 2016 | 246 | 1.020 |
Why?
| | Cross-Sectional Studies | 42 | 2026 | 5868 | 1.010 |
Why?
| | Vasodilation | 8 | 2025 | 523 | 1.000 |
Why?
| | Adrenergic beta-Antagonists | 7 | 2011 | 250 | 0.990 |
Why?
| | Prevalence | 27 | 2024 | 2834 | 0.980 |
Why?
| | Prospective Studies | 42 | 2025 | 7990 | 0.970 |
Why?
| | Vascular Diseases | 7 | 2021 | 251 | 0.950 |
Why?
| | Obesity | 6 | 2026 | 3077 | 0.950 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 741 | 0.920 |
Why?
| | Community Health Workers | 2 | 2026 | 87 | 0.910 |
Why?
| | Hyperparathyroidism, Secondary | 4 | 2009 | 12 | 0.880 |
Why?
| | Renal Insufficiency | 7 | 2025 | 168 | 0.860 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 461 | 0.860 |
Why?
| | Minerals | 6 | 2022 | 47 | 0.840 |
Why?
| | Cognition | 6 | 2023 | 1266 | 0.830 |
Why?
| | Acute Kidney Injury | 10 | 2022 | 865 | 0.820 |
Why?
| | Curcumin | 2 | 2021 | 25 | 0.820 |
Why?
| | Cohort Studies | 32 | 2024 | 5960 | 0.810 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 100 | 0.780 |
Why?
| | Anemia | 5 | 2020 | 188 | 0.760 |
Why?
| | Proportional Hazards Models | 30 | 2019 | 1325 | 0.740 |
Why?
| | Follow-Up Studies | 37 | 2020 | 5408 | 0.740 |
Why?
| | Albuminuria | 13 | 2022 | 190 | 0.740 |
Why?
| | Overweight | 3 | 2026 | 609 | 0.730 |
Why?
| | Pregnancy Complications | 3 | 2018 | 592 | 0.730 |
Why?
| | Aged, 80 and over | 43 | 2023 | 8265 | 0.720 |
Why?
| | Incidence | 28 | 2021 | 2879 | 0.720 |
Why?
| | Non-alcoholic Fatty Liver Disease | 9 | 2016 | 266 | 0.720 |
Why?
| | Atherosclerosis | 8 | 2021 | 409 | 0.710 |
Why?
| | Weight Gain | 1 | 2026 | 556 | 0.710 |
Why?
| | Vascular Surgical Procedures | 13 | 2011 | 339 | 0.700 |
Why?
| | Metformin | 2 | 2024 | 318 | 0.690 |
Why?
| | Kidney Tubules | 5 | 2024 | 117 | 0.680 |
Why?
| | Kidney Function Tests | 12 | 2017 | 157 | 0.670 |
Why?
| | Patient Navigation | 4 | 2026 | 104 | 0.670 |
Why?
| | Vitamins | 3 | 2022 | 178 | 0.660 |
Why?
| | Calcimimetic Agents | 1 | 2020 | 3 | 0.660 |
Why?
| | Kidney Transplantation | 3 | 2022 | 704 | 0.660 |
Why?
| | Hyponatremia | 2 | 2018 | 43 | 0.650 |
Why?
| | Calcitriol | 2 | 2018 | 58 | 0.650 |
Why?
| | Cystatin C | 7 | 2013 | 65 | 0.640 |
Why?
| | Sodium | 2 | 2019 | 197 | 0.640 |
Why?
| | Diabetic Nephropathies | 6 | 2025 | 318 | 0.630 |
Why?
| | Systole | 8 | 2020 | 178 | 0.630 |
Why?
| | Bicarbonates | 5 | 2023 | 45 | 0.630 |
Why?
| | Renal Artery Obstruction | 3 | 2014 | 29 | 0.620 |
Why?
| | Treatment Outcome | 39 | 2025 | 11679 | 0.620 |
Why?
| | Renin-Angiotensin System | 3 | 2017 | 78 | 0.620 |
Why?
| | Bone Diseases | 1 | 2020 | 61 | 0.620 |
Why?
| | Time Factors | 30 | 2022 | 7173 | 0.610 |
Why?
| | Odds Ratio | 13 | 2024 | 1075 | 0.610 |
Why?
| | Interleukin-1 | 3 | 2019 | 961 | 0.600 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 47 | 0.600 |
Why?
| | Prognosis | 27 | 2021 | 4282 | 0.590 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.570 |
Why?
| | United States | 36 | 2026 | 15966 | 0.570 |
Why?
| | Chronic Disease | 19 | 2017 | 1813 | 0.570 |
Why?
| | Cause of Death | 6 | 2018 | 471 | 0.570 |
Why?
| | Simvastatin | 3 | 2014 | 60 | 0.560 |
Why?
| | Acidosis | 2 | 2018 | 105 | 0.550 |
Why?
| | Young Adult | 24 | 2025 | 14105 | 0.550 |
Why?
| | Calcium, Dietary | 2 | 2009 | 53 | 0.550 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 68 | 0.550 |
Why?
| | Heart Diseases | 4 | 2015 | 349 | 0.550 |
Why?
| | Hypertrophy, Left Ventricular | 4 | 2017 | 124 | 0.550 |
Why?
| | Hemoglobins | 4 | 2009 | 384 | 0.540 |
Why?
| | Caloric Restriction | 4 | 2024 | 127 | 0.540 |
Why?
| | Arterial Pressure | 1 | 2018 | 136 | 0.530 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 675 | 0.530 |
Why?
| | Accidental Falls | 1 | 2020 | 222 | 0.530 |
Why?
| | Endothelial Cells | 5 | 2023 | 869 | 0.520 |
Why?
| | Death, Sudden, Cardiac | 5 | 2015 | 230 | 0.520 |
Why?
| | Carotid Artery Diseases | 3 | 2021 | 69 | 0.520 |
Why?
| | Frailty | 1 | 2020 | 198 | 0.520 |
Why?
| | Calcinosis | 6 | 2017 | 234 | 0.510 |
Why?
| | Diet | 4 | 2025 | 1273 | 0.510 |
Why?
| | Multivariate Analysis | 14 | 2017 | 1539 | 0.510 |
Why?
| | Logistic Models | 12 | 2024 | 2117 | 0.510 |
Why?
| | Interleukin-6 | 2 | 2020 | 780 | 0.500 |
Why?
| | Bone Density | 5 | 2017 | 482 | 0.500 |
Why?
| | Renal Circulation | 3 | 2026 | 75 | 0.490 |
Why?
| | Calciphylaxis | 1 | 2016 | 2 | 0.490 |
Why?
| | Longitudinal Studies | 17 | 2020 | 2947 | 0.490 |
Why?
| | Uremia | 1 | 2016 | 15 | 0.490 |
Why?
| | Dementia | 4 | 2025 | 303 | 0.480 |
Why?
| | Conservative Treatment | 1 | 2017 | 44 | 0.480 |
Why?
| | Pregnancy Outcome | 3 | 2018 | 476 | 0.480 |
Why?
| | Sodium Chloride | 1 | 2017 | 141 | 0.480 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 221 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 12 | 2023 | 1720 | 0.460 |
Why?
| | Primary Prevention | 3 | 2018 | 220 | 0.460 |
Why?
| | Hyperuricemia | 5 | 2018 | 47 | 0.460 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 38 | 0.460 |
Why?
| | Fluid Therapy | 1 | 2017 | 147 | 0.460 |
Why?
| | Peripheral Vascular Diseases | 7 | 2012 | 104 | 0.450 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2014 | 392 | 0.440 |
Why?
| | Insulin Resistance | 7 | 2025 | 1241 | 0.440 |
Why?
| | Myocardial Infarction | 10 | 2017 | 1209 | 0.440 |
Why?
| | Diabetes Complications | 6 | 2018 | 222 | 0.440 |
Why?
| | Comorbidity | 13 | 2018 | 1658 | 0.440 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2012 | 2583 | 0.430 |
Why?
| | Liver | 2 | 2016 | 1887 | 0.430 |
Why?
| | Undocumented Immigrants | 3 | 2023 | 64 | 0.430 |
Why?
| | Retrospective Studies | 33 | 2024 | 17066 | 0.430 |
Why?
| | Peripheral Arterial Disease | 7 | 2021 | 503 | 0.420 |
Why?
| | Body Mass Index | 11 | 2026 | 2438 | 0.420 |
Why?
| | Fructose | 2 | 2016 | 130 | 0.420 |
Why?
| | Risk Assessment | 24 | 2021 | 3671 | 0.410 |
Why?
| | Cardiovascular Agents | 4 | 2013 | 164 | 0.410 |
Why?
| | Survival Rate | 14 | 2020 | 2089 | 0.410 |
Why?
| | Pyrazoles | 2 | 2014 | 509 | 0.400 |
Why?
| | Hyperphosphatemia | 4 | 2020 | 15 | 0.400 |
Why?
| | Sodium Nitrite | 3 | 2021 | 39 | 0.390 |
Why?
| | Ankle Brachial Index | 4 | 2014 | 41 | 0.390 |
Why?
| | Pyridines | 2 | 2014 | 605 | 0.390 |
Why?
| | C-Reactive Protein | 8 | 2018 | 416 | 0.390 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 113 | 0.390 |
Why?
| | Aging | 6 | 2026 | 1966 | 0.380 |
Why?
| | Disease Management | 2 | 2026 | 645 | 0.380 |
Why?
| | TRPP Cation Channels | 5 | 2022 | 74 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3863 | 0.380 |
Why?
| | Nephrolithiasis | 1 | 2012 | 9 | 0.370 |
Why?
| | Antioxidants | 3 | 2026 | 549 | 0.370 |
Why?
| | Organ Size | 3 | 2025 | 463 | 0.360 |
Why?
| | Magnesium | 2 | 2014 | 155 | 0.360 |
Why?
| | Chi-Square Distribution | 10 | 2017 | 529 | 0.360 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.360 |
Why?
| | Radius | 1 | 2012 | 52 | 0.360 |
Why?
| | Hemostasis | 2 | 2009 | 102 | 0.360 |
Why?
| | Carotid Arteries | 4 | 2018 | 207 | 0.360 |
Why?
| | Case-Control Studies | 12 | 2025 | 3604 | 0.350 |
Why?
| | Heart Ventricles | 2 | 2013 | 760 | 0.350 |
Why?
| | Hypothyroidism | 2 | 2009 | 67 | 0.340 |
Why?
| | Mitochondria | 3 | 2026 | 984 | 0.340 |
Why?
| | Health Status | 3 | 2015 | 836 | 0.330 |
Why?
| | Health Surveys | 3 | 2014 | 518 | 0.330 |
Why?
| | Independent Living | 5 | 2018 | 114 | 0.330 |
Why?
| | Coronary Artery Bypass | 3 | 2014 | 268 | 0.330 |
Why?
| | Kaplan-Meier Estimate | 14 | 2018 | 965 | 0.330 |
Why?
| | Colorado | 11 | 2026 | 4564 | 0.330 |
Why?
| | Blood Coagulation Disorders | 2 | 2010 | 189 | 0.330 |
Why?
| | Resistance Training | 2 | 2023 | 182 | 0.330 |
Why?
| | Physical Fitness | 1 | 2012 | 209 | 0.330 |
Why?
| | NAD | 2 | 2023 | 81 | 0.320 |
Why?
| | Internship and Residency | 2 | 2020 | 1257 | 0.320 |
Why?
| | Hip Fractures | 3 | 2017 | 84 | 0.320 |
Why?
| | Hypercapnia | 3 | 2025 | 54 | 0.310 |
Why?
| | Homeostasis | 5 | 2018 | 640 | 0.310 |
Why?
| | Ischemia | 3 | 2011 | 421 | 0.310 |
Why?
| | Dyslipidemias | 2 | 2013 | 181 | 0.310 |
Why?
| | Lovastatin | 1 | 2009 | 37 | 0.310 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 71 | 0.300 |
Why?
| | Zinc | 1 | 2012 | 295 | 0.300 |
Why?
| | Mortality | 5 | 2020 | 375 | 0.300 |
Why?
| | gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.300 |
Why?
| | Blood Coagulation | 3 | 2011 | 268 | 0.300 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.300 |
Why?
| | Weight Loss | 1 | 2015 | 836 | 0.290 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 4 | 2024 | 41 | 0.290 |
Why?
| | Hospitals, Veterans | 2 | 2008 | 259 | 0.290 |
Why?
| | Lipocalin-2 | 4 | 2024 | 79 | 0.290 |
Why?
| | Fibrinolysis | 2 | 2011 | 162 | 0.290 |
Why?
| | Uromodulin | 5 | 2022 | 22 | 0.290 |
Why?
| | Hospitalization | 3 | 2016 | 2433 | 0.280 |
Why?
| | Bilirubin | 1 | 2009 | 97 | 0.280 |
Why?
| | Regional Blood Flow | 5 | 2017 | 514 | 0.280 |
Why?
| | Bone and Bones | 2 | 2012 | 314 | 0.280 |
Why?
| | Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.270 |
Why?
| | Sepsis | 1 | 2014 | 640 | 0.270 |
Why?
| | Severity of Illness Index | 12 | 2020 | 2925 | 0.270 |
Why?
| | Coronary Angiography | 3 | 2012 | 323 | 0.270 |
Why?
| | Cross-Over Studies | 6 | 2026 | 601 | 0.260 |
Why?
| | Magnetic Resonance Angiography | 2 | 2025 | 251 | 0.260 |
Why?
| | Aorta | 3 | 2021 | 429 | 0.250 |
Why?
| | Ultrasonography | 6 | 2013 | 770 | 0.250 |
Why?
| | Adolescent | 14 | 2023 | 22428 | 0.240 |
Why?
| | Metabolomics | 4 | 2022 | 727 | 0.240 |
Why?
| | Aortic Aneurysm, Abdominal | 6 | 2011 | 167 | 0.240 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 114 | 0.240 |
Why?
| | Brain | 2 | 2018 | 2933 | 0.240 |
Why?
| | Infant, Low Birth Weight | 2 | 2018 | 153 | 0.240 |
Why?
| | Electric Countershock | 1 | 2007 | 127 | 0.240 |
Why?
| | Professional Competence | 1 | 2006 | 98 | 0.240 |
Why?
| | Ubiquinone | 1 | 2026 | 35 | 0.240 |
Why?
| | Infant Mortality | 2 | 2018 | 123 | 0.240 |
Why?
| | Coronary Vessels | 3 | 2022 | 251 | 0.230 |
Why?
| | Thrombosis | 1 | 2009 | 393 | 0.230 |
Why?
| | Anticholesteremic Agents | 1 | 2007 | 152 | 0.220 |
Why?
| | Deoxycholic Acid | 3 | 2022 | 14 | 0.220 |
Why?
| | Fasting | 4 | 2023 | 277 | 0.220 |
Why?
| | Organophosphorus Compounds | 1 | 2026 | 85 | 0.220 |
Why?
| | Respiratory Muscles | 2 | 2023 | 36 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 45 | 0.220 |
Why?
| | Nitric Oxide | 5 | 2023 | 897 | 0.220 |
Why?
| | Wine | 1 | 2024 | 13 | 0.220 |
Why?
| | Blood Pressure Determination | 3 | 2020 | 144 | 0.220 |
Why?
| | Cognition Disorders | 3 | 2017 | 538 | 0.220 |
Why?
| | Survival Analysis | 6 | 2019 | 1382 | 0.210 |
Why?
| | Beer | 1 | 2024 | 13 | 0.210 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 121 | 0.210 |
Why?
| | Tryptophan | 2 | 2023 | 181 | 0.210 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 204 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2020 | 985 | 0.210 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 10 | 0.210 |
Why?
| | Pilot Projects | 5 | 2025 | 1886 | 0.210 |
Why?
| | Inflammasomes | 1 | 2025 | 146 | 0.210 |
Why?
| | Linear Models | 6 | 2017 | 854 | 0.200 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 46 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2014 | 3890 | 0.200 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 44 | 0.200 |
Why?
| | Animals | 16 | 2026 | 38058 | 0.200 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 338 | 0.200 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 280 | 0.200 |
Why?
| | Nutritional Status | 2 | 2018 | 354 | 0.200 |
Why?
| | Quality of Life | 4 | 2020 | 3185 | 0.200 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 37 | 0.200 |
Why?
| | Confidence Intervals | 3 | 2012 | 333 | 0.190 |
Why?
| | Terminology as Topic | 1 | 2025 | 255 | 0.190 |
Why?
| | Drug Therapy, Combination | 6 | 2020 | 1047 | 0.190 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2021 | 108 | 0.190 |
Why?
| | Metabolome | 3 | 2022 | 384 | 0.190 |
Why?
| | Self-Management | 1 | 2025 | 201 | 0.190 |
Why?
| | Recovery of Function | 3 | 2017 | 707 | 0.180 |
Why?
| | Up-Regulation | 5 | 2019 | 851 | 0.180 |
Why?
| | Compassion Fatigue | 1 | 2022 | 31 | 0.180 |
Why?
| | Age Factors | 9 | 2025 | 3333 | 0.180 |
Why?
| | Troponin T | 3 | 2012 | 65 | 0.180 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2014 | 230 | 0.180 |
Why?
| | Diastole | 3 | 2013 | 143 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2006 | 589 | 0.180 |
Why?
| | Child | 9 | 2023 | 22633 | 0.180 |
Why?
| | Physicians | 2 | 2022 | 939 | 0.180 |
Why?
| | Military Personnel | 1 | 2009 | 741 | 0.180 |
Why?
| | Heart Failure | 8 | 2017 | 2323 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Sex Factors | 7 | 2025 | 2112 | 0.170 |
Why?
| | Exercise Tolerance | 1 | 2023 | 283 | 0.170 |
Why?
| | Atrial Fibrillation | 2 | 2020 | 550 | 0.170 |
Why?
| | Niacinamide | 2 | 2020 | 86 | 0.170 |
Why?
| | Toxins, Biological | 1 | 2020 | 12 | 0.170 |
Why?
| | Propanolamines | 2 | 2011 | 40 | 0.170 |
Why?
| | Education | 2 | 2018 | 104 | 0.170 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2115 | 0.160 |
Why?
| | Parathyroidectomy | 1 | 2020 | 9 | 0.160 |
Why?
| | Diabetes Mellitus | 4 | 2020 | 1098 | 0.160 |
Why?
| | Osteoporotic Fractures | 2 | 2012 | 61 | 0.160 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 75 | 0.160 |
Why?
| | Culturally Competent Care | 1 | 2021 | 74 | 0.160 |
Why?
| | Motor Activity | 2 | 2015 | 721 | 0.160 |
Why?
| | Netherlands | 8 | 2012 | 82 | 0.160 |
Why?
| | Sevelamer | 1 | 2020 | 9 | 0.160 |
Why?
| | Neutrophils | 1 | 2006 | 1134 | 0.160 |
Why?
| | Intestinal Absorption | 1 | 2021 | 103 | 0.160 |
Why?
| | Stroke | 4 | 2017 | 1256 | 0.160 |
Why?
| | Placebos | 2 | 2012 | 192 | 0.160 |
Why?
| | Plaque, Atherosclerotic | 1 | 2021 | 60 | 0.160 |
Why?
| | Allopurinol | 2 | 2018 | 69 | 0.160 |
Why?
| | Propensity Score | 2 | 2019 | 367 | 0.160 |
Why?
| | Hypokalemia | 1 | 2020 | 24 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 1185 | 0.160 |
Why?
| | Communication Barriers | 1 | 2021 | 124 | 0.160 |
Why?
| | Tunica Intima | 3 | 2010 | 79 | 0.150 |
Why?
| | Acetates | 1 | 2020 | 80 | 0.150 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1326 | 0.150 |
Why?
| | Hyperkalemia | 1 | 2020 | 35 | 0.150 |
Why?
| | Feasibility Studies | 2 | 2021 | 1095 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2025 | 509 | 0.150 |
Why?
| | Age Distribution | 2 | 2012 | 403 | 0.150 |
Why?
| | Sex Distribution | 2 | 2012 | 386 | 0.150 |
Why?
| | Mice | 9 | 2026 | 18339 | 0.150 |
Why?
| | Preoperative Period | 4 | 2014 | 149 | 0.150 |
Why?
| | Energy Metabolism | 2 | 2024 | 935 | 0.150 |
Why?
| | Adiposity | 1 | 2024 | 543 | 0.150 |
Why?
| | Focus Groups | 2 | 2020 | 573 | 0.150 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 265 | 0.150 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 154 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 846 | 0.140 |
Why?
| | Patient Care Planning | 1 | 2020 | 169 | 0.140 |
Why?
| | Calcification, Physiologic | 1 | 2018 | 29 | 0.140 |
Why?
| | Neuroimaging | 2 | 2018 | 289 | 0.140 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 101 | 0.140 |
Why?
| | Potassium | 2 | 2020 | 152 | 0.140 |
Why?
| | Scandinavian and Nordic Countries | 2 | 2008 | 14 | 0.140 |
Why?
| | Carnitine | 1 | 2018 | 90 | 0.140 |
Why?
| | Information Seeking Behavior | 1 | 2018 | 38 | 0.140 |
Why?
| | Reactive Oxygen Species | 4 | 2023 | 621 | 0.140 |
Why?
| | Pain | 2 | 2020 | 779 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1560 | 0.140 |
Why?
| | Electrocardiography | 5 | 2020 | 662 | 0.130 |
Why?
| | Cholesterol, HDL | 4 | 2013 | 200 | 0.130 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 37 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2018 | 6429 | 0.130 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 56 | 0.130 |
Why?
| | Healthy Aging | 1 | 2018 | 40 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2024 | 826 | 0.130 |
Why?
| | Adaptive Immunity | 1 | 2018 | 169 | 0.130 |
Why?
| | Emergency Treatment | 1 | 2018 | 124 | 0.130 |
Why?
| | Hemodialysis Solutions | 1 | 2017 | 3 | 0.130 |
Why?
| | Death | 1 | 2018 | 130 | 0.130 |
Why?
| | Femoral Artery | 1 | 2018 | 190 | 0.130 |
Why?
| | Fellowships and Scholarships | 2 | 2020 | 357 | 0.130 |
Why?
| | Postoperative Complications | 6 | 2014 | 2919 | 0.120 |
Why?
| | Vasopressins | 1 | 2017 | 60 | 0.120 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 18 | 0.120 |
Why?
| | Preoperative Care | 2 | 2010 | 379 | 0.120 |
Why?
| | Living Donors | 1 | 2018 | 280 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2017 | 120 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2003 | 823 | 0.120 |
Why?
| | Peer Group | 1 | 2019 | 257 | 0.120 |
Why?
| | Cholesterol, LDL | 3 | 2013 | 358 | 0.120 |
Why?
| | Trehalose | 1 | 2016 | 35 | 0.120 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 104 | 0.120 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1134 | 0.120 |
Why?
| | Bile Acids and Salts | 1 | 2017 | 164 | 0.120 |
Why?
| | Postoperative Period | 3 | 2011 | 354 | 0.120 |
Why?
| | Health Services Accessibility | 3 | 2021 | 1098 | 0.120 |
Why?
| | Vascular Resistance | 2 | 2014 | 367 | 0.120 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 151 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 484 | 0.120 |
Why?
| | Mutation | 3 | 2022 | 4089 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2017 | 272 | 0.110 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2015 | 66 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 276 | 0.110 |
Why?
| | Heart Rate | 2 | 2011 | 855 | 0.110 |
Why?
| | Phosphatidylethanolamines | 1 | 2015 | 76 | 0.110 |
Why?
| | Risk Reduction Behavior | 2 | 2015 | 226 | 0.110 |
Why?
| | Heart Arrest | 2 | 2016 | 407 | 0.110 |
Why?
| | Analysis of Variance | 3 | 2012 | 1306 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2017 | 163 | 0.110 |
Why?
| | Frail Elderly | 1 | 2016 | 134 | 0.110 |
Why?
| | Obstetric Labor, Premature | 1 | 2015 | 39 | 0.110 |
Why?
| | Risk | 5 | 2019 | 911 | 0.110 |
Why?
| | Pregnancy | 3 | 2018 | 7190 | 0.110 |
Why?
| | Global Health | 2 | 2015 | 401 | 0.110 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2015 | 120 | 0.110 |
Why?
| | Aorta, Abdominal | 2 | 2012 | 52 | 0.110 |
Why?
| | Maternal Mortality | 1 | 2015 | 53 | 0.110 |
Why?
| | Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 995 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 2027 | 0.110 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 2 | 0.110 |
Why?
| | Metabolic Diseases | 2 | 2014 | 114 | 0.110 |
Why?
| | Italy | 5 | 2014 | 113 | 0.110 |
Why?
| | Acetylcholine | 3 | 2023 | 204 | 0.110 |
Why?
| | Serine | 1 | 2015 | 145 | 0.110 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 32 | 0.110 |
Why?
| | Estrogen Replacement Therapy | 2 | 2014 | 144 | 0.100 |
Why?
| | Renal Artery | 1 | 2014 | 43 | 0.100 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 202 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 479 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2014 | 31 | 0.100 |
Why?
| | Organophosphonates | 1 | 2014 | 97 | 0.100 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.100 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.100 |
Why?
| | Infant, Small for Gestational Age | 1 | 2015 | 109 | 0.100 |
Why?
| | Steroid Hydroxylases | 1 | 2013 | 20 | 0.100 |
Why?
| | Tocopherols | 1 | 2013 | 30 | 0.100 |
Why?
| | Hand Strength | 2 | 2026 | 144 | 0.100 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2013 | 22 | 0.100 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.100 |
Why?
| | Qualitative Research | 4 | 2025 | 1671 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 129 | 0.100 |
Why?
| | Aortic Valve Stenosis | 2 | 2017 | 253 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2017 | 284 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1519 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2026 | 5992 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1047 | 0.100 |
Why?
| | Premature Birth | 1 | 2017 | 380 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 824 | 0.100 |
Why?
| | Cesarean Section | 1 | 2015 | 224 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2013 | 73 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2019 | 727 | 0.090 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 771 | 0.090 |
Why?
| | Institutionalization | 1 | 2012 | 12 | 0.090 |
Why?
| | Ferric Compounds | 1 | 2012 | 55 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 557 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Adenine | 1 | 2014 | 339 | 0.090 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2024 | 18 | 0.090 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 266 | 0.090 |
Why?
| | Causality | 2 | 2011 | 126 | 0.090 |
Why?
| | Cytokines | 2 | 2018 | 2061 | 0.090 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.090 |
Why?
| | Tunica Media | 2 | 2010 | 37 | 0.090 |
Why?
| | Glycation End Products, Advanced | 1 | 2012 | 82 | 0.090 |
Why?
| | Aortic Aneurysm | 1 | 2012 | 70 | 0.090 |
Why?
| | Sympathetic Nervous System | 2 | 2015 | 178 | 0.090 |
Why?
| | Echocardiography, Stress | 2 | 2010 | 29 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 279 | 0.090 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 174 | 0.090 |
Why?
| | Chemokine CCL2 | 2 | 2024 | 115 | 0.090 |
Why?
| | Postoperative Care | 2 | 2010 | 288 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2011 | 59 | 0.090 |
Why?
| | Hemostatic Disorders | 1 | 2011 | 1 | 0.080 |
Why?
| | International Classification of Diseases | 1 | 2012 | 147 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2014 | 1030 | 0.080 |
Why?
| | Models, Biological | 3 | 2024 | 1821 | 0.080 |
Why?
| | Cardiovascular System | 3 | 2020 | 137 | 0.080 |
Why?
| | Drug Combinations | 1 | 2012 | 390 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2637 | 0.080 |
Why?
| | Heart Failure, Systolic | 1 | 2010 | 27 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Muscle Strength | 2 | 2023 | 330 | 0.080 |
Why?
| | Gout | 1 | 2010 | 35 | 0.080 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 111 | 0.080 |
Why?
| | Ticlopidine | 1 | 2010 | 54 | 0.080 |
Why?
| | Infant, Premature | 1 | 2015 | 611 | 0.080 |
Why?
| | Thinness | 1 | 2010 | 99 | 0.080 |
Why?
| | Alpha-Globulins | 2 | 2020 | 19 | 0.080 |
Why?
| | beta 2-Microglobulin | 2 | 2020 | 47 | 0.080 |
Why?
| | Aneurysm | 1 | 2009 | 37 | 0.080 |
Why?
| | Proteinuria | 2 | 2014 | 102 | 0.080 |
Why?
| | Nisoldipine | 1 | 2009 | 7 | 0.070 |
Why?
| | Enalapril | 1 | 2009 | 16 | 0.070 |
Why?
| | Genetic Loci | 1 | 2010 | 261 | 0.070 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 90 | 0.070 |
Why?
| | Radioisotope Renography | 1 | 2008 | 4 | 0.070 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 103 | 0.070 |
Why?
| | Regression Analysis | 3 | 2019 | 1003 | 0.070 |
Why?
| | Length of Stay | 1 | 2015 | 1337 | 0.070 |
Why?
| | Texas | 1 | 2009 | 278 | 0.070 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2008 | 37 | 0.070 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 30 | 0.070 |
Why?
| | Population Groups | 1 | 2009 | 58 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 88 | 0.070 |
Why?
| | Chelating Agents | 2 | 2020 | 71 | 0.070 |
Why?
| | Delphi Technique | 2 | 2020 | 329 | 0.070 |
Why?
| | Databases as Topic | 1 | 2008 | 71 | 0.070 |
Why?
| | Perindopril | 1 | 2007 | 1 | 0.070 |
Why?
| | Demography | 1 | 2009 | 288 | 0.070 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 208 | 0.070 |
Why?
| | Osteogenesis | 2 | 2021 | 208 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2008 | 83 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2014 | 928 | 0.060 |
Why?
| | Infant | 3 | 2018 | 10034 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 969 | 0.060 |
Why?
| | Aspirin | 1 | 2010 | 399 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 372 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2010 | 699 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2023 | 3121 | 0.060 |
Why?
| | Estradiol | 1 | 2010 | 533 | 0.060 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2010 | 497 | 0.060 |
Why?
| | Testosterone | 1 | 2010 | 419 | 0.060 |
Why?
| | Forearm | 2 | 2017 | 140 | 0.060 |
Why?
| | Triglycerides | 3 | 2013 | 520 | 0.060 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2025 | 29 | 0.060 |
Why?
| | Protective Factors | 2 | 2016 | 99 | 0.060 |
Why?
| | Contrast Media | 1 | 2008 | 488 | 0.060 |
Why?
| | Calcifediol | 1 | 2024 | 31 | 0.050 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 56 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2011 | 846 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1180 | 0.050 |
Why?
| | Phagocytosis | 1 | 2006 | 299 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 463 | 0.050 |
Why?
| | Outpatients | 1 | 2008 | 442 | 0.050 |
Why?
| | Vegetables | 1 | 2025 | 170 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1833 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 851 | 0.050 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 79 | 0.050 |
Why?
| | Hemodialysis, Home | 1 | 2023 | 9 | 0.050 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2025 | 180 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | Self-Help Groups | 1 | 2023 | 37 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 111 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 126 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 391 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 128 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 55 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 333 | 0.050 |
Why?
| | Least-Squares Analysis | 2 | 2012 | 76 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2194 | 0.050 |
Why?
| | NADPH Oxidases | 2 | 2013 | 124 | 0.050 |
Why?
| | Midazolam | 1 | 2022 | 72 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 847 | 0.040 |
Why?
| | Waist Circumference | 2 | 2012 | 139 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 413 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 242 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 299 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 920 | 0.040 |
Why?
| | Activating Transcription Factor 4 | 1 | 2021 | 22 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2022 | 177 | 0.040 |
Why?
| | Endocannabinoids | 1 | 2022 | 57 | 0.040 |
Why?
| | Caregivers | 2 | 2020 | 1049 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 241 | 0.040 |
Why?
| | Social Isolation | 1 | 2021 | 72 | 0.040 |
Why?
| | Hematinics | 1 | 2020 | 22 | 0.040 |
Why?
| | Hepcidins | 1 | 2020 | 22 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1053 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3162 | 0.040 |
Why?
| | Nephrologists | 1 | 2020 | 14 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 248 | 0.040 |
Why?
| | Administrative Personnel | 1 | 2020 | 33 | 0.040 |
Why?
| | Acute Disease | 2 | 2017 | 1030 | 0.040 |
Why?
| | Calcium Compounds | 1 | 2020 | 6 | 0.040 |
Why?
| | Asia | 1 | 2020 | 70 | 0.040 |
Why?
| | Biopsy | 1 | 2003 | 1075 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1266 | 0.040 |
Why?
| | Serum Albumin | 1 | 2020 | 147 | 0.040 |
Why?
| | Vitamin B Complex | 1 | 2020 | 40 | 0.040 |
Why?
| | Africa | 1 | 2020 | 116 | 0.040 |
Why?
| | California | 2 | 2012 | 475 | 0.040 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1387 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2020 | 84 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2021 | 214 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 37 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4557 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 398 | 0.040 |
Why?
| | Models, Animal | 1 | 2021 | 392 | 0.040 |
Why?
| | HIV Infections | 1 | 2014 | 3154 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2020 | 103 | 0.040 |
Why?
| | Glucuronidase | 1 | 2018 | 25 | 0.040 |
Why?
| | Health Literacy | 1 | 2021 | 184 | 0.040 |
Why?
| | Social Stigma | 1 | 2021 | 171 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 673 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 576 | 0.040 |
Why?
| | Patients | 1 | 2020 | 180 | 0.030 |
Why?
| | Symptom Flare Up | 1 | 2018 | 37 | 0.030 |
Why?
| | Sodium Chloride Symporter Inhibitors | 1 | 2018 | 8 | 0.030 |
Why?
| | Urban Population | 1 | 2021 | 491 | 0.030 |
Why?
| | Aftercare | 1 | 2020 | 223 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 237 | 0.030 |
Why?
| | Self Concept | 1 | 2020 | 253 | 0.030 |
Why?
| | Publications | 1 | 2018 | 48 | 0.030 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 31 | 0.030 |
Why?
| | Registries | 2 | 2021 | 2385 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 488 | 0.030 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 169 | 0.030 |
Why?
| | Fathers | 1 | 2018 | 51 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 548 | 0.030 |
Why?
| | NF-kappa B | 2 | 2012 | 661 | 0.030 |
Why?
| | Intelligence Tests | 1 | 2017 | 56 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2021 | 395 | 0.030 |
Why?
| | Mitral Valve Stenosis | 1 | 2017 | 20 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 235 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 165 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 406 | 0.030 |
Why?
| | Femur Neck | 1 | 2017 | 62 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 499 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 441 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2018 | 125 | 0.030 |
Why?
| | Diuretics | 1 | 2016 | 68 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 691 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 199 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 488 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 172 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1985 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 370 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2026 | 1795 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 947 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 454 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 200 | 0.030 |
Why?
| | White Matter | 1 | 2017 | 153 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 184 | 0.030 |
Why?
| | Research | 1 | 2018 | 431 | 0.030 |
Why?
| | Renal Elimination | 1 | 2014 | 5 | 0.030 |
Why?
| | Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| | Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| | Urinalysis | 1 | 2015 | 80 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 331 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 195 | 0.030 |
Why?
| | Ketocholesterols | 1 | 2014 | 8 | 0.030 |
Why?
| | France | 1 | 2014 | 40 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 551 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2014 | 40 | 0.030 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 94 | 0.030 |
Why?
| | Research Design | 2 | 2011 | 1135 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2019 | 704 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 145 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 236 | 0.030 |
Why?
| | Azetidines | 1 | 2014 | 45 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 901 | 0.030 |
Why?
| | F2-Isoprostanes | 1 | 2013 | 20 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 887 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2014 | 94 | 0.030 |
Why?
| | Aortic Valve | 1 | 2017 | 365 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2014 | 61 | 0.030 |
Why?
| | Needs Assessment | 1 | 2017 | 404 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 20 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2013 | 57 | 0.030 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 293 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 653 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2021 | 4154 | 0.020 |
Why?
| | Pulse | 1 | 2013 | 27 | 0.020 |
Why?
| | Health Personnel | 1 | 2020 | 748 | 0.020 |
Why?
| | Program Evaluation | 1 | 2018 | 948 | 0.020 |
Why?
| | Immunoblotting | 1 | 2013 | 300 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2182 | 0.020 |
Why?
| | Executive Function | 1 | 2018 | 461 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2363 | 0.020 |
Why?
| | Signal Transduction | 2 | 2018 | 5226 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 118 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2882 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 370 | 0.020 |
Why?
| | Random Allocation | 1 | 2013 | 363 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 779 | 0.020 |
Why?
| | Tenofovir | 1 | 2014 | 295 | 0.020 |
Why?
| | Xanthine Oxidase | 1 | 2012 | 79 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 142 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2012 | 85 | 0.020 |
Why?
| | Germany | 1 | 2012 | 138 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 138 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2018 | 1125 | 0.020 |
Why?
| | Ventricular Remodeling | 1 | 2014 | 276 | 0.020 |
Why?
| | Blood Glucose | 2 | 2012 | 2327 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2013 | 1047 | 0.020 |
Why?
| | Insulin | 2 | 2013 | 2507 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 775 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2020 | 1152 | 0.020 |
Why?
| | Metoprolol | 1 | 2011 | 26 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 119 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 71 | 0.020 |
Why?
| | Nitroglycerin | 1 | 2010 | 14 | 0.020 |
Why?
| | Aortic Diseases | 1 | 2012 | 124 | 0.020 |
Why?
| | Salicylates | 1 | 2010 | 29 | 0.020 |
Why?
| | Arteries | 1 | 2012 | 259 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 372 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Stroke Volume | 1 | 2013 | 651 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 423 | 0.020 |
Why?
| | Sunlight | 1 | 2010 | 78 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 301 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 330 | 0.020 |
Why?
| | Life Style | 1 | 2012 | 479 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 710 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2009 | 18 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 652 | 0.020 |
Why?
| | Cystatins | 1 | 2008 | 7 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2010 | 201 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2010 | 285 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 614 | 0.020 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2008 | 30 | 0.020 |
Why?
| | Dobutamine | 1 | 2007 | 24 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2527 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 323 | 0.020 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 157 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1313 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2310 | 0.010 |
Why?
| | Hemodynamics | 1 | 2011 | 1121 | 0.010 |
Why?
| | Exercise | 1 | 2018 | 2201 | 0.010 |
Why?
| | Perioperative Care | 1 | 2008 | 231 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2013 | 1173 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5597 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 541 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1406 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6048 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|